idarubicin has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 51 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (3.92) | 18.7374 |
| 1990's | 23 (45.10) | 18.2507 |
| 2000's | 18 (35.29) | 29.6817 |
| 2010's | 7 (13.73) | 24.3611 |
| 2020's | 1 (1.96) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, J; Chen, Y; Dong, QF; Hu, JD; Li, F; Luo, LT; Sang, YQ; Wang, J; Wang, SL; Yang, T; Ye, YZ; Zhang, L; Zheng, J; Zheng, XY | 1 |
| Chen, B; Chen, D; Guan, C; Peng, M; Shao, X; Xie, P; Xu, P; Yuan, C | 1 |
| Arsikin, K; Bogdanovic, A; Bosnjak, M; Bumbasirevic, V; Harhaji-Trajkovic, L; Kravic-Stevovic, T; Martinovic, T; Mircic, A; Perovic, V; Ristic, B; Suzin-Zivkovic, V; Trajkovic, V | 1 |
| Akhtari, M; Armitage, JO; Bhatt, VR; Bociek, RG; Dave, BJ; Kessinger, A; Sanger, WG; Sanmann, JN; Yuan, J | 1 |
| Non, LR; Pande, A; Romee, R; Santos, CA | 1 |
| Borthakur, G; Cortes, J; Jones, D; Kantarjian, HM; Luthra, R; Rios, MB; Verma, D; Verstovsek, S | 1 |
| Arslan, M; Erkut, M; Erkut, N; Ersoz, S; Sonmez, M | 1 |
| Maia, RC; Nestal de Moraes, G; Silva, KL; Vasconcelos, FC | 1 |
| Kim, DH; Kim, JI; Kim, WS; Kim, YC; Lee, JE; Lee, MJ; Park, SG; Song, MR | 1 |
| Al-Ali, HK; Bumm, T; Deininger, MW; Franke, C; Friedrich, T; Hennig, E; Krahl, R; Krohn, K; Leiblein, S; Müller, C; Niederwieser, D; Schmidt, E; Shepherd, P | 1 |
| Cortes, JE; Douer, D; Estey, EH; Faderl, S; Garcia-Manero, G; Giles, FJ; Jeha, SS; Kantarjian, HM; Koller, CA; Levine, AM; O'Brien, SM; Thomas, DA | 1 |
| Giakoumi, X; Mantzouranis, M; Pangalis, GA; Vassilakopoulos, TP; Viniou, NA | 1 |
| Ahmed, P; Anwar, M; Hashmi, KU; Hussain, I; Iqbal, H; Khan, B; Mahmood, A; Malik, HS; Raza, S | 1 |
| Bousquet, M; Brousset, P; Dastugue, N; De Mas, V; Delsol, G; Duchayne, E; Laurent, G; Quelen, C; Roquefeuil, B | 1 |
| Austin, CA; Ayuso, MJ; Azrak, SS; Cortés, F; López-Lázaro, M; Pastor, N | 1 |
| Cortes, J; Faderl, S; Garcia-Manero, G; Giles, F; Kantarjian, H; O'Brien, S; Quintás-Cardama, A; Ravandi, F; Thomas, D; Wierda, W | 1 |
| Chang, HJ; Cho, MS; Choi, MY; Kong, JH; Kwon, JM; Lee, KE; Lee, SM; Lee, SN; Mun, YC; Nam, E; Nam, SH; Seong, CM; Yoo, SH | 1 |
| Bergamaschi, G; Carella, AM; Cazzola, M; Ferrero, R; Podestá, M; Pollicardo, N; Pungolino, E; Raffo, MR; Rosti, V; Saglio, G | 1 |
| Carella, AM; Ferrero, R; Frassoni, F; Podestá, M; Pollicardo, N; Pungolino, E; Soracco, M | 1 |
| Baccarani, M; Baraldo, M; Damiani, D; Fanin, R; Furlanut, M; Michelutti, A; Michieli, M; Pea, F; Russo, D | 1 |
| Davey, MW; Davey, RA; Hargrave, RM; Kidman, AD | 1 |
| Carella, AM; Frassoni, F; Parodi, C; Podesta, M; Pollicardo, N; Pungolino, E; Rabitti, C; Raffo, MR; Sessarego, M; Vimercati, R | 1 |
| Chalmers, EA; Clarke, R; Franklin, IM; Goldstone, AH; Hepplestone, A; Kelsey, S; Sharp, S; Sproul, AM; Tansey, P; Watson, W | 1 |
| Calvert, L; Claxton, D; Durett, A; Giralt, S; Hamer, J; Kantarjian, H; Khouri, I; Liang, J; Talpaz, M; Tibbits, P | 1 |
| Benvenuto, F; Carella, AM; Ferrero, R; Figari, O; Frassoni, F; Giordano, D; Podestà, M; Pollicardo, N; Pungolino, E; Raffo, MR | 1 |
| Buscaglia, MD; Minderman, H; Rustum, YM | 1 |
| Pratila, MG; Pratilas, V; Steinherz, LJ | 1 |
| Baccarani, M; Damiani, D; Fanin, R; Michelutti, A; Michieli, M; Russo, D | 1 |
| Chen, PM; Chiou, TJ; Fan, FS; Hsieh, RK; Liu, JH; Tzeng, CH; Wei, CH; Yu, IT | 1 |
| Carella, AM; Frassoni, F | 1 |
| Aulitzky, WE; Busemann, C; Huber, C; Huhn, D; Kolbe, K; Neubauer, A; Peschel, C; Schleiermacher, E; Schneller, F; Siegert, W | 1 |
| Capria, S; Mandelli, F; Meloni, G; Modena, V; Vignetti, M | 1 |
| Hall, JL; Hamblin, TJ; Myint, H; Ross, FM | 1 |
| Avramis, VI; Dinndorf, PA; Kelleher, JF; Krailo, MD; Liu-Mares, W; Mosher, RB; Reaman, GH; Sato, JK; Seibel, NL; Wiersma, S | 1 |
| Badri, N; Boogaerts, M; Carella, AM; Dabouz-Harrouche, F; Gautier, L; Gorin, NC; Lennard, A; Link, H; Simonsson, B; Tomas-Martinez, JF | 1 |
| Bode, U; Fleischhack, G; Graf, N; Hasan, C; Mann, G | 1 |
| Baer, MR; Herzig, GP; Jenis, EH; Mookerjee, BK; Schriber, JR; Shah, M; Wetzler, M | 1 |
| Aulitzky, W; Huber, C; Peschel, C; Schneller, F; Schuler, M; Schumacher, K; Thaler, J | 1 |
| Mandelli, F; Montefusco, E | 1 |
| Menéndez, B; Salar, A; Sierra, J; Sureda, A | 1 |
| Cuello, T; Gargallo, P; Larripa, I; Vellón, L | 1 |
| Cornelissen, JJ; Hagemeijer, A; Janssen, JJ; Nieuwint, AW; Ossenkoppele, GJ; Schuurhuis, GJ; Släter, R; van den Berg, E; van der Holt, B; van Rijn, RS; Vellenga, E; Verhoef, GE | 1 |
| de Witte, T; Preijers, F; Schaap, N; Schattenberg, A; van der Maazen, R | 1 |
| Chen, X; Greinix, HT; Haas, OA; Kalhs, P; Keil, F; Lechner, K; Loidolt, H; Louda, N; Mannhalter, C; Mitterbauer, G; Moser, K; Pirc-Danoewinata, H; Rabitsch, W; Worel, N | 1 |
| Baer, MR; Barone, S; Block, AW; Lawrence, D; Sait, SN; Wetzler, M | 1 |
| Dachselt, K; Deininger, M; Doepper, J; Dölken, G; Edel, E; Fiedler, F; Franke, A; Freund, M; Helbig, W; Herold, M; Hoffmann, FA; Kettner, E; Krahl, R; Lange, T; Leiblein, S; Niederwieser, D; Pasold, R; Pönisch, W; Richter, P; Schultze, W; Schwalbe, E; Schwarzer, A; Steglich, J; Subert, R; Uhle, R; von Grünhagen, U; Winkelmann, C | 1 |
| Banyai, A; Barta, A; Foldi, J; Gidali, J; Gopcsa, L; Kalasz, L; Pajor, L; Paloczi, K; Regeczy, N | 1 |
| Döhner, H; Gabler, A; Haas, R; Hartmann, F; Hensel, M; Ho, AD; Jung, W; Schlenk, RF; Trümper, L; Weber-Nordt, R | 1 |
| Fujita, H; Kimura, K; Masaoka, T; Ogawa, M; Yamada, K | 1 |
| Andreeff, M; Berman, E; Clarkson, BD; Gabrilove, J; Gee, TS; Gulati, S; Kempin, SJ; Raymond, V; Wiernik, PH; Young, CW | 1 |
| Andreeff, M; Berman, E; Gabrilove, J; Gee, T; Gulati, S; Heller, G; Kempin, SJ; Kolitz, J; Raymond, V; Young, CW | 1 |
4 review(s) available for idarubicin and Leukemia, Myelogenous, Chronic, BCR-ABL Positive
| Article | Year |
|---|---|
Pseudozyma and other non-Candida opportunistic yeast bloodstream infections in a large stem cell transplant center.
Topics: Adult; Amphotericin B; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cryptococcus; Cytarabine; Dermatomycoses; Echinocandins; Exanthema; Fever; Fungemia; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunocompromised Host; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lipopeptides; Male; Micafungin; Opportunistic Infections; Retrospective Studies; Saccharomyces; Salvage Therapy; Trichosporon; Ustilaginales; Vidarabine; Voriconazole; Yeasts | 2017 |
Mobilisation of Ph-negative peripheral blood stem cells in CML with idarubicin and cytarabine.
Topics: Cell Separation; Cytarabine; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Idarubicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Transplantation, Autologous | 1994 |
Interferon-alpha-associated focal segmental glomerulosclerosis with massive proteinuria in patients with chronic myeloid leukemia following high dose chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Glomerulosclerosis, Focal Segmental; Hematopoietic Stem Cell Mobilization; Humans; Idarubicin; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Proteinuria | 1998 |
[Treatment of acute and chronic leukemias].
Topics: Acute Disease; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chromosome Aberrations; Combined Modality Therapy; Daunorubicin; Humans; Idarubicin; Karyotyping; Leukemia; Leukemia, Hairy Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Randomized Controlled Trials as Topic; Transplantation, Autologous; Transplantation, Homologous | 1999 |
13 trial(s) available for idarubicin and Leukemia, Myelogenous, Chronic, BCR-ABL Positive
| Article | Year |
|---|---|
Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Cytosine; Dioxolanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Idarubicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Topotecan; Treatment Outcome | 2003 |
Idarubicin-containing regimen and G-CSF are capable of recruiting CD34+/DR- cells with high proliferative potential which sustain Ph-negative polyclonal hematopoiesis.
Topics: Adult; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoiesis; HLA-DR Antigens; Humans; Idarubicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Middle Aged | 1994 |
Idarubicin, intermediate-dose cytarabine, etoposide, and granulocyte-colony-stimulating factor are able to recruit CD34+/HLA-DR- cells during early hematopoietic recovery in accelerated and chronic phases of chronic myeloid leukemia.
Topics: Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cells; HLA-DR Antigens; Humans; Idarubicin; Interferon-alpha; Leukapheresis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Philadelphia Chromosome; Treatment Outcome | 1994 |
Preliminary results of stem cell mobilization in chronic myeloid leukemia with a moderate intensity chemotherapy regimen and G-CSF or G-CSF plus IL-3.
Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Drug Resistance; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Idarubicin; Interferon-alpha; Interleukin-3; Leukapheresis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Middle Aged; Philadelphia Chromosome | 1996 |
Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Female; Humans; Idarubicin; Infant; Infusions, Intravenous; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Vidarabine | 1997 |
IDA-FLAG (idarubicin, fludarabine, cytarabine, G-CSF), an effective remission-induction therapy for poor-prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: experiences of a phase II trial.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Remission Induction; Vidarabine | 1998 |
Idarubicin and intermediate-dose cytarabine for myeloid blast crisis of chronic myelogenous leukemia--results of a phase-II trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Idarubicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Remission Induction; Survival Rate | 1998 |
Mobilisation of haemopoietic progenitors in CML: a second course of intensive chemotherapy does not improve Ph-negativity in stem cell harvests.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Transplantation, Autologous | 2000 |
High-dose cytosine arabinoside and idarubicin treatment of chronic myeloid leukemia in myeloid blast crisis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Cytogenetic Analysis; Dose-Response Relationship, Drug; Female; Humans; Idarubicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pilot Projects; Remission Induction; Survival Rate; Treatment Outcome | 2001 |
Chemotherapy for mobilisation of Ph-negative progenitor cells from patients with CML: impact of different mobilisation regimens.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Idarubicin; Interferon-alpha; Leukapheresis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome | 2001 |
Less intense conditioning with fludarabine, cyclophosphamide, idarubicin and etoposide (FCIE) followed by allogeneic unselected peripheral blood stem cell transplantation in elderly patients with leukemia.
Topics: Adult; Aged; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Cyclosporine; Etoposide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2002 |
Idarubicin in acute leukemia: results of US trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Evaluation; Humans; Idarubicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute | 1989 |
Idarubicin in acute leukemia: results of studies at Memorial Sloan-Kettering Cancer Center.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction | 1989 |
34 other study(ies) available for idarubicin and Leukemia, Myelogenous, Chronic, BCR-ABL Positive
| Article | Year |
|---|---|
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Female; Forkhead Transcription Factors; Humans; Idarubicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies; RNA, Messenger; T-Lymphocytes, Regulatory; Transforming Growth Factor beta | 2023 |
Primary Philadelphia chromosome positive acute myeloid leukemia: A case report.
Topics: Antineoplastic Agents; Bone Marrow Examination; Cytarabine; Dasatinib; Flow Cytometry; Fusion Proteins, bcr-abl; Humans; Idarubicin; Karyotype; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Multiple Organ Failure; Mutation; Philadelphia Chromosome | 2018 |
Idarubicin induces mTOR-dependent cytotoxic autophagy in leukemic cells.
Topics: Adult; Antibiotics, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Cell Proliferation; Humans; Idarubicin; Immunoenzyme Techniques; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocytes; Membrane Potential, Mitochondrial; Membrane Proteins; Microscopy, Electron, Scanning; Microscopy, Fluorescence; Phosphorylation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogene Proteins c-akt; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Cells, Cultured | 2014 |
Allogeneic stem cell transplantation for Philadelphia chromosome-positive acute myeloid leukemia.
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Benzamides; Consolidation Chemotherapy; Cyclophosphamide; Cytarabine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Imatinib Mesylate; Immunosuppressive Agents; Induction Chemotherapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Transplantation, Homologous; Treatment Outcome; Young Adult | 2014 |
Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Cyclophosphamide; Cytarabine; Dasatinib; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Fusion Proteins, bcr-abl; Humans; Idarubicin; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Survival Rate; Thiazoles; Vincristine | 2009 |
A case of acute colitis with severe rectal bleeding in a patient with chronic myeloid leukemia after dasatinib use.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Colitis; Cytarabine; Dasatinib; Female; Gastrointestinal Hemorrhage; Humans; Idarubicin; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Rectal Diseases; Thiazoles | 2010 |
Survivin overexpression correlates with an apoptosis-resistant phenotype in chronic myeloid leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Cycle; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Idarubicin; Inhibitor of Apoptosis Proteins; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phenotype; Survivin; Up-Regulation | 2011 |
5'-OH-5-nitro-Indirubin oxime (AGM130), an Indirubin derivative, induces apoptosis of Imatinib-resistant chronic myeloid leukemia cells.
Topics: Apoptosis; Benzamides; Humans; Idarubicin; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2013 |
Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Benzamides; Blood Cells; Bone Marrow Cells; Clone Cells; Cohort Studies; Cytarabine; Dosage Compensation, Genetic; Enzyme Inhibitors; Female; Fusion Proteins, bcr-abl; Hematopoiesis; Humans; Idarubicin; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Myelodysplastic Syndromes; Philadelphia Chromosome; Piperazines; Pyrimidines; Receptors, Androgen; Remission Induction | 2003 |
Ida-FLAG plus imatinib mesylate-induced molecular remission in a patient with chemoresistant Ph1+ acute myeloid leukemia.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Recombinant Proteins; Salvage Therapy; Treatment Outcome; Vidarabine | 2004 |
FLAG-IDA in the treatment of refractory/relapsed acute leukaemias: single centre study.
Topics: Acute Disease; Adolescent; Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Vidarabine | 2005 |
The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Autoantigens; Cell Cycle Proteins; Chromosomes, Human, Pair 8; Chromosomes, Human, Pair 9; Cytarabine; Fatal Outcome; Genetic Variation; Humans; Hydroxyurea; Idarubicin; In Situ Hybridization, Fluorescence; Janus Kinase 2; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Oncogene Proteins, Fusion; Open Reading Frames; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Secondary Prevention; Sequence Analysis, RNA; Translocation, Genetic; Treatment Outcome | 2005 |
Digitoxin, at concentrations commonly found in the plasma of cardiac patients, antagonizes etoposide and idarubicin activity in K562 leukemia cells.
Topics: Amsacrine; Antineoplastic Agents; Digitoxin; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Etoposide; Humans; Idarubicin; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mitoxantrone; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2006 |
A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Idarubicin; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pilot Projects; Piperazines; Pyrimidines; Survival Rate; Treatment Outcome | 2007 |
Early imatinib-mesylate-induced hepatotoxicity in chronic myelogenous leukaemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bile Ducts; Blast Crisis; Chemical and Drug Induced Liver Injury; Cholestasis, Intrahepatic; Cytarabine; Drug Eruptions; Hepatocytes; Humans; Idarubicin; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver Function Tests; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2007 |
P170-related multidrug resistance. Enhancement of idarubicin content in leukemic cells with cyclosporin in vivo: a report of two cases.
Topics: Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclosporine; Drug Resistance, Multiple; Humans; Idarubicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Male; Middle Aged | 1995 |
Development of drug resistance is reduced with idarubicin relative to other anthracyclines.
Topics: Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Cell Survival; Drug Interactions; Drug Resistance, Multiple; Etoposide; Flow Cytometry; Humans; Idarubicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Tumor Cells, Cultured; Verapamil | 1995 |
Collection of 'normal' blood repopulating cells during early hemopoietic recovery after intensive conventional chemotherapy in chronic myelogenous leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Component Transfusion; Blood Transfusion, Autologous; Cell Separation; Combined Modality Therapy; Cytarabine; Etoposide; Female; Fusion Proteins, bcr-abl; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Idarubicin; Immunologic Factors; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Polymerase Chain Reaction; Recombinant Proteins; Remission Induction; RNA, Messenger; RNA, Neoplasm; Time Factors; Treatment Outcome | 1993 |
Percentage of Philadelphia chromosome (Ph)-negative and Ph-positive cells found after autologous transplantation for chronic myelogenous leukemia depends on percentage of diploid cells induced by conventional-dose chemotherapy before collection of autolog
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow Transplantation; Cell Survival; Colony-Forming Units Assay; Combined Modality Therapy; Cyclophosphamide; Daunorubicin; Diploidy; Etoposide; Female; Genetic Markers; Hematopoietic Stem Cells; Humans; Idarubicin; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Mitoxantrone; Neoplastic Stem Cells; Philadelphia Chromosome; Remission Induction; Survival Rate; Vidarabine; Whole-Body Irradiation | 1995 |
Selective overshoot of Ph-negative blood hemopoietic cells after intensive idarubicin-containing regimen and their repopulating capacity after reinfusion.
Topics: Adult; Blast Crisis; Bone Marrow Transplantation; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Idarubicin; Leukapheresis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Middle Aged | 1993 |
Schedule-dependent efficacy of idarubicin (Ida) and doxorubicin (Dox).
Topics: Cell Division; Cell Line; Cell Survival; Dose-Response Relationship, Drug; Doxorubicin; Flow Cytometry; Humans; Idarubicin; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Time Factors; Tumor Cells, Cultured | 1994 |
Sick sinus syndrome in a teenager treated with idarubicin.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arrhythmia, Sinus; Bradycardia; Cytarabine; Humans; Idarubicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Sick Sinus Syndrome | 1993 |
P170 glycoprotein expression and impaired anthracycline retention in chronic myeloid leukaemia.
Topics: Antibodies, Monoclonal; ATP Binding Cassette Transporter, Subfamily B, Member 1; Daunorubicin; Drug Resistance, Multiple; Flow Cytometry; Humans; Idarubicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase | 1995 |
Trisomy 21 in acute myeloid leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Down Syndrome; Humans; Hydroxyurea; Idarubicin; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myelomonocytic, Acute; Male; Mitoxantrone | 1996 |
Collection, analysis and transplantation of Ph-negative blood precursor cells in chronic myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukapheresis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Recurrence; Remission Induction; Transplantation, Autologous | 1996 |
Blast crisis of chronic myelogenous leukemia in long-lasting systemic lupus erythematosus: regression of both diseases after autologous bone marrow transplantation.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Blast Crisis; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Female; Humans; Idarubicin; Immunologic Factors; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lupus Erythematosus, Systemic; Methotrexate; Prednisone; Remission Induction; Transplantation, Autologous; Vincristine | 1997 |
Early transformation to acute myeloblastic leukaemia with the acquisition of inv(16) in Ph positive chronic granulocytic leukaemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosome Disorders; Chromosome Inversion; Chromosome Mapping; Chromosomes, Human, Pair 16; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Cytarabine; Fatal Outcome; Humans; Idarubicin; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Philadelphia Chromosome | 1997 |
Mobilization of Philadelphia-negative peripheral blood progenitor cells with chemotherapy and rhuG-CSF in chronic myelogenous leukaemia patients with a poor response to interferon-alpha.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Cytarabine; Daunorubicin; Etoposide; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Interferon-alpha; Lenograstim; Leukapheresis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Male; Middle Aged; Recombinant Proteins; Treatment Outcome | 1998 |
Mini-ICE regimen allows mobilization of peripheral blood progenitor cells in a patient with chronic myelogenous leukemia failing the ICE protocol.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarabine; Etoposide; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Idarubicin; Ifosfamide; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male | 2000 |
[Antisense oligonucleotides increase the apoptotic effect of idarubicin in K-562 cell line].
Topics: Antibiotics, Antineoplastic; Apoptosis; Humans; Idarubicin; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oligonucleotides, Antisense | 2000 |
Outcome of T cell-depleted transplantation after conditioning with an intensified regimen in patients aged 50 years or more is comparable with that in younger patients.
Topics: Adolescent; Adult; Age Factors; Bone Marrow Transplantation; Cyclophosphamide; Female; Graft vs Host Disease; Humans; Idarubicin; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Lymphocyte Depletion; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; Survival Rate; T-Lymphocytes | 2000 |
PBPC mobilization with chemotherapy and G-CSF in patients with chronic myeloid leukemia: quantification of bcr/abl-positive cells by interphase fluorescence in situ hybridization and competitive PCR.
Topics: Adult; Cell Nucleus; Chronic Disease; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Idarubicin; In Situ Hybridization, Fluorescence; Interphase; Leukapheresis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Oncogene Proteins; Polymerase Chain Reaction; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-bcr | 2001 |
Autologous hematopoietic stem cell transplantation in chronic myeloid leukemia with different clinical stages.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow Purging; Caspase 14; Caspases; Cell Survival; Colony-Forming Units Assay; Combined Modality Therapy; Cytarabine; Etoposide; Female; Filgrastim; Fusion Proteins, bcr-abl; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunologic Factors; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Male; Recombinant Proteins; Remission Induction; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2001 |
[A pharmacokinetic study of idarubicin hydrochloride, a new anthracycline anti-tumor drug, in patients with acute leukemia. Idarubicin Study Group].
Topics: Acute Disease; Blast Crisis; Humans; Idarubicin; Infusions, Intravenous; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1992 |